Current and emerging targeted therapies for metastatic breast cancer
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current and emerging targeted therapies for metastatic breast cancer
Authors
Keywords
-
Journal
CANCER
Volume 118, Issue 12, Pages 3014-3025
Publisher
Wiley
Online
2011-10-18
DOI
10.1002/cncr.26356
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer
- (2017) D. Slamon et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)
- (2017) S. Modi et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial
- (2017) J. O'Shaughnessy et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC).
- (2017) J. Crown et al. JOURNAL OF CLINICAL ONCOLOGY
- A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC).
- (2017) J. O'Shaughnessy et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T).
- (2017) K. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trial.
- (2017) F. Dalenc et al. JOURNAL OF CLINICAL ONCOLOGY
- BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than two prior chemotherapies.
- (2017) M. H. Schuler et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2, to letrozole in estrogen receptor (ER)-positive metastatic breast cancer (mBC) progressing on letrozole monotherapy.
- (2017) K. Gunzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC).
- (2017) J. Bergh et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
- (2012) Edith A. Perez et al. MAYO CLINIC PROCEEDINGS
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the Phosphatidylinositol 3-Kinase Signaling Pathway in Breast Cancer
- (2011) L. F. Hernandez-Aya et al. ONCOLOGIST
- Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059.
- (2010) RS Finn et al. CANCER RESEARCH
- Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab.
- (2010) T. Hickish et al. CANCER RESEARCH
- Targeting DNA repair in breast cancer: A clinical and translational update
- (2010) Eitan Amir et al. CANCER TREATMENT REVIEWS
- Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor—2 tyrosine kinases used in the treatment of breast cancer
- (2010) Amye J. Tevaarwerk et al. CLINICAL THERAPEUTICS
- Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab
- (2010) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
- (2010) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer
- (2009) M. Kozloff et al. ANNALS OF ONCOLOGY
- Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
- (2009) Giulia Bianchi et al. ANTI-CANCER DRUGS
- Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
- (2009) Susan L. Ellard et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller
- (2009) Ana M. Gonzalez-Angulo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
- (2009) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
- (2009) A. Craig Lockhart et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines
- (2008) P. Schmid et al. ANNALS OF ONCOLOGY
- Targeting Src in breast cancer
- (2008) R. S. Finn ANNALS OF ONCOLOGY
- Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study
- (2008) A Awada et al. BRITISH JOURNAL OF CANCER
- Guideline implementation for breast healthcare in low-income and middle-income countries
- (2008) Benjamin O. Anderson et al. CANCER
- Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer
- (2008) Rupert Bartsch et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- HER2-Positive Breast Cancer: From Trastuzumab to Innovatory Anti-HER2 Strategies
- (2008) Nicolas Whenham et al. Clinical Breast Cancer
- A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
- (2008) T. H. Luu et al. CLINICAL CANCER RESEARCH
- Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
- (2008) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2008) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336
- (2008) Alvaro Moreno-Aspitia et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now